Article
Oncology
Sherif Mohamed Elsharkawi, Dalal Elkaffash, Pacint Moez, Nour El-Etreby, Eman Sheta, Raghda Saad Zaghloul Taleb
Summary: This study compared the methylation status of the PCDH17 gene promoter between females diagnosed with epithelial ovarian cancer and a control group. It found that the methylation levels were significantly higher in ovarian cancer patients compared to the control group.
Article
Genetics & Heredity
N. Kuzub, V. Smialkovska, V. Momot, V. Moseiko, O. Lushchak, A. Koliada
Summary: Epigenetic clocks are models that use CpG methylation levels to predict the age of an organism. In this study, two epigenetic clock models based on 4 CpG sites and 2 CpG sites were evaluated, and both showed good age predictive accuracy in the Ukrainian population. The models had small prediction errors for individuals aged 18 to 80.
FRONTIERS IN GENETICS
(2022)
Review
Biochemistry & Molecular Biology
Eshaan Patnaik, Chikezie Madu, Yi Lu
Summary: Epigenetics plays a crucial role in gene regulation and tumor development. DNA methylation inhibitors and histone deacetylase inhibitors can restore normal gene expression and be effective against cancer. Understanding epigenetic modifications and utilizing inhibitors offer new possibilities for cancer research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pathology
Hongxing Nan, Lisha Zhou, Weihua Liang, Jin Meng, Ke Lin, Man Li, Jun Hou, Lianghai Wang
Summary: Elevated expression of CCL20 in esophageal cancer is associated with poor prognosis and metastatic potential, as well as with promoter hypomethylation in tumor cells. Imbalance among CD4(+) T cell subtypes and abnormal CCL20 expression in the tumor microenvironment are observed during tumorigenesis. Targeting CCL20 may be a promising therapeutic approach for esophageal cancer.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Flavia E. Rius, Debora D. Papaiz, Hatylas F. Z. Azevedo, Ana Luisa P. Ayub, Diogo O. Pessoa, Tiago F. Oliveira, Ana Paula M. Loureiro, Fernando Andrade, Andre Fujita, Eduardo M. Reis, Christopher E. Mason, Miriam G. Jasiulionis
Summary: This study identified novel CpG methylation markers associated with malignancy and metastasis in melanoma. These markers were correlated with melanoma prognosis and could improve survival prediction.
CLINICAL EPIGENETICS
(2022)
Review
Multidisciplinary Sciences
Chuan Teng, Fanhua Kong, Jinggang Mo, Weidong Lin, Chong Jin, Kunpeng Wang, Ying Wang
Summary: Esophageal cancer is a malignancy with a high degree of malignancy and mortality, and its pathogenesis and treatment strategies are not well understood. N-6-methyladenosine (m(6)A) plays an important role in RNA modification and its role in esophageal cancer is still unknown. RNA methylation regulators, including "writers" (methyltransferases), "erasers" (demethylases), and "readers" (modified RNA-binding proteins), regulate RNA modification and splicing, affecting the occurrence, development, invasion, and metastasis of tumors. Reviewing the role of these regulators in esophageal cancer can contribute to the understanding of its pathogenesis and the development of therapeutic approaches.
Article
Immunology
Huimei Wang, Yiping Zhang, Lin Chen, Yufeng Liu, Chen Xu, Dongxian Jiang, Qi Song, Haixing Wang, Liyan Wang, Yu Lin, Yuanmei Chen, Junqiang Chen, Yuanji Xu, Yingyong Hou
Summary: This study found significant differential expression of most of the 23 regulators in ESCA tissues. LASSO regression analysis identified 7 m6A-related factors, and the risk model was associated with biological functions such as base metabolism, DNA repair, and mismatch repair. A nomogram was created to predict the prognosis of ESCA patients, and bioinformatics analysis of human ESCA and normal tissues was performed using qRT-PCR.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Dipanwita Das, Nandini Karthik, Reshma Taneja
Summary: Inflammation is a crucial immune response against infection and tissue damage, but chronic inflammation is linked to cancer development. Immune cells produce inflammatory mediators to facilitate tumor growth, while aberrant expression of inflammatory factors by tumor cells recruits immune cells for mutual crosstalk, creating a conducive environment for tumor growth.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Caterina Strisciuglio, Felicity Payne, Komal Nayak, Marialuisa Andreozzi, Alessandra Vitale, Erasmo Miele, Matthias Zilbauer
Summary: The study found significant differences in mucosal DNA methylation profiles between children diagnosed with EoE and the control group, highlighting the potential for these epigenetic signatures to be developed into clinically applicable biomarkers.
CLINICAL EPIGENETICS
(2021)
Review
Biochemistry & Molecular Biology
Sarah S. Wang, Jihao Xu, Keely Y. Ji, Chang-Il Hwang
Summary: Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDA), is a significant cause of cancer-related deaths in the United States. While genetic mutations driving PDA initiation and progression have been identified, the mechanisms underlying PDA metastasis remain elusive. It is suggested that epigenetic fluctuations may play a critical role in driving PDA metastasis.
Review
Oncology
Yuhao Zhao, Mao Yang, Shijia Wang, Sk Jahir Abbas, Junzhe Zhang, Yongsheng Li, Rong Shao, Yingbin Liu
Summary: This review focuses on the mechanistic insights of DNA, histone, and RNA methylation in regulating the progression of pancreatic cancer. The roles of methylation regulators in modulating gene expression associated with cell proliferation, invasion, and apoptosis are discussed. Recent clinical trials on methylation drug targeting are also explored. Understanding the novel regulatory mechanisms of methylation modification may offer alternative opportunities to improve therapeutic efficacy in combating this devastating disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ling Lv, Jianzhong Ma, Lina Wu, Chao Zhang, Yueping Wang, Guang Wang
Summary: This study found that the transcriptional inactivation of the FBN1 gene may start from normal colonic epithelium, and the FBN1 gene methylation catalyzed by DNMT gradually generates powerful force, accelerates expansion, and eventually leads to colorectal cancer (CRC). FBN1 methylation is a promising biomarker, and the FBN1 methylation risk size in feces reflects the non-invasive detection results in tissue.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Renzo J. M. Riemens, Gunter Kenis, Jennifer Nolz, Sonia C. Susano C. Chaves, Diane Duroux, Ehsan Pishva, Diego Mastroeni, Kristel Van Steen, Thomas Haaf, Daniel L. A. van den Hove
Summary: A novel approach combining LCM and LDBSP is developed to quantify and analyze the DNA methylation patterns of individual genes in neuronal cells. The method proves to be efficient and accurate, providing further validity to this approach in neuroepigenomic studies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Veronica Davalos, Manel Esteller
Summary: Cancer development is caused by changes in the structure and function of the genome. Epigenetic alterations regulate gene expression programs that promote tumorigenesis and can be used as useful tools in clinical decision making. Unlike genetic changes, epigenetic modifications can be reversed, making them an attractive target for drug development.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Pharmacology & Pharmacy
Ruijie Zeng, Shujie Huang, Xinqi Qiu, Zewei Zhuo, Huihuan Wu, Lei Jiang, Weihong Sha, Hao Chen
Summary: A pyroptosis-related five-gene signature correlated with the survival of esophageal adenocarcinoma patients has been identified and a prognostic nomogram based on the signature has been constructed. Downregulation of GSDMB within the signature may be associated with enhanced DNA methylation, and the signature is potentially related to immune response and regulation of the tumor microenvironment. Several inhibitors show promise in reversing the altered differentially expressed genes in high-risk patients, providing insights into the involvement of pyroptosis in EAC progression and potential implications for risk assessment and prognosis in clinical practice.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Surgery
Naoya Yoshida, Keisuke Kosumi, Ryuma Tokunaga, Baba Yoshifumi, Yohei Nagai, Yuji Miyamoto, Shiro Iwagami, Masaaki Iwatsuki, Yukiharu Hiyoshi, Takatsugu Ishimoto, Kojiro Eto, Yu Imamura, Masayuki Watanabe, Hideo Baba
Article
Oncology
Masayo Tsukamoto, Katsunori Imai, Takatsugu Ishimoto, Yoshihiro Komohara, Yo-ichi Yamashita, Shigeki Nakagawa, Naoki Umezaki, Takanobu Yamao, Yuki Kitano, Tatsunori Miyata, Kota Arima, Hirohisa Okabe, Yoshifumi Baba, Akira Chikamoto, Takatoshi Ishiko, Masahiko Hirota, Hideo Baba
Review
Biochemistry & Molecular Biology
Luke Bu, Hideo Baba, Naoya Yoshida, Keisuke Miyake, Tadahito Yasuda, Tomoyuki Uchihara, Patrick Tan, Takatsugu Ishimoto
Article
Cell Biology
Daisuke Izumi, Shusuke Toden, Elsie Ureta, Takatsugu Ishimoto, Hideo Baba, Ajay Goel
CELL DEATH & DISEASE
(2019)
Article
Gastroenterology & Hepatology
Yohei Nagai, Naoya Yoshida, Yoshifumi Baba, Kazuto Harada, Katsunori Imai, Masaaki Iwatsuki, Ryuichi Karashima, Yuki Koga, Daichi Nomoto, Kazuo Okadome, Takatsugu Ishimoto, Yu Imamura, Masayuki Watanabe, Hideo Baba
DIGESTIVE ENDOSCOPY
(2020)
Article
Oncology
Kohei Yamashita, Masaaki Iwatsuki, Kazuto Harada, Kojiro Eto, Yukiharu Hiyoshi, Takatsugu Ishimoto, Yohei Nagai, Shiro Iwagami, Yuji Miyamoto, Naoya Yoshida, Yoshihiro Komohara, Jaffer A. Ajani, Hideo Baba
Article
Oncology
Kosuke Mima, Yuki Sakamoto, Keisuke Kosumi, Yoko Ogata, Keisuke Miyake, Yukiharu Hiyoshi, Takatsugu Ishimoto, Masaaki Iwatsuki, Yoshifumi Baba, Shiro Iwagami, Yuji Miyamoto, Naoya Yoshida, Shuji Ogino, Hideo Baba
SURGICAL ONCOLOGY-OXFORD
(2020)
Article
Oncology
Naoya Yoshida, Yuki Adachi, Takeshi Morinaga, Kojiro Eto, Ryuma Tokunaga, Kazuto Harada, Yukiharu Hiyoshi, Yohei Nagai, Masaaki Iwatsuki, Takatsugu Ishimoto, Yoshifumi Baba, Shiro Iwagami, Yuji Miyamoto, Yu Imamura, Masayuki Watanabe, Hideo Baba
ANNALS OF SURGICAL ONCOLOGY
(2020)
Article
Oncology
Kazuo Okadome, Yoshifumi Baba, Daichi Nomoto, Taisuke Yagi, Rebecca Kalikawe, Kazuto Harada, Yukiharu Hiyoshi, Yohei Nagai, Takatsugu Ishimoto, Masaaki Iwatsuki, Shiro Iwagami, Yuji Miyamoto, Naoya Yoshida, Masayuki Watanabe, Yoshihiro Komohara, Takashi Shono, Yutaka Sasaki, Hideo Baba
BRITISH JOURNAL OF CANCER
(2020)
Review
Biochemistry & Molecular Biology
Sana Hibino, Tetsuro Kawazoe, Hidenori Kasahara, Shinji Itoh, Takatsugu Ishimoto, Mamiko Sakata-Yanagimoto, Koji Taniguchi
Summary: Inflammation plays a pivotal role in tumorigenesis and metastasis by suppressing anti-tumor immunity. Different types of tumors may have diverse responses to inflammation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Surgery
Tadahito Yasuda, Kojiro Eto, Naoya Yoshida, Shiro Iwagami, Yukiharu Hiyoshi, Youhei Nagai, Masaaki Iwatsuki, Takatsugu Ishimoto, Yoshifumi Baba, Yuji Miyamoto, Takuya Shiota, Yoshiki Mikami, Hideo Baba
SURGICAL CASE REPORTS
(2020)
Review
Biochemistry & Molecular Biology
Lingfeng Fu, Luke Bu, Tadahito Yasuda, Mayu Koiwa, Takahiko Akiyama, Tomoyuki Uchihara, Hideo Baba, Takatsugu Ishimoto
Meeting Abstract
Oncology
Kazuo Okadome, Yoshifumi Baba, Taisuke Yagi, Yuki Kiyozumi, Kojiro Eto, Yukiharu Hiyoshi, Yohei Nagai, Takatsugu Ishimoto, Masaaki Iwatsuki, Shiro Iwagami, Yuji Miyamoto, Naoya Yoshida, Hideo Baba
Meeting Abstract
Oncology
Yuki Sakamoto, Kosuke Mima, Nobuya Daitoku, Yukiharu Hiyoshi, Katsunori Imai, Masaaki Iwatsuki, Takatsugu Ishimoto, Yoshifumi Baba, Shiro Iwagami, Yuji Miyamoto, Yoichi Yamashita, Naoya Yoshida, Hideo Baba
Meeting Abstract
Oncology
Takatsugu Ishimoto, Kota Arima, Tomoyuki Uchihara, Keisuke Miyake, Atsuko Yonemura, Tadahito Yasuda, Rumi Itoyama, Masaaki Iwatsuki, Yoshifumi Baba, Naoya Yoshida, Hideo Baba